Skip to main content

BridgeBio Pharma, Inc. (BBIO) Stock Analysis

SellVALUE-TRAP 3/5Moderate Confidence

Healthcare · Biotechnology

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $71.17 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk).

BridgeBio Pharma is a commercial-stage biopharmaceutical company whose primary product Attruby (acoramidis) was FDA-approved in November 2024 for transthyretin amyloid cardiomyopathy, priced at $19,790 per 28-day supply in 2026. The company has treated 8,500+ patients with... Read more

$71.17+27.6% A.UpsideScore 5.3/10#50 of 158 Biotechnology
Stop $66.30Target $90.80(analyst − 10%)A.R:R 2.4:1
Analyst target$100.89+41.8%23 analysts
$90.80our TP
$71.17price
$100.89mean
$157

Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $71.17 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, news boost analyst cluster(3), semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: moderate.

Val3.3Qual5.1Grw10.0Mom2.1Sent8.6Ins3.3Peer4.1Tech7.7Risk3.55.3OVERALL

Thesis

Rewards
Positive news sentiment (+0.75)
Strong growth profile
Analyst upside: 28%
Risks
Concentration risk — Product: Attruby and Beyonttra
Earnings in 5 days (event risk)
Consecutive earnings misses (2)

Key Metrics

P/E (TTM)—
P/E (Fwd)134.5
Mkt Cap$13.8B
EV/EBITDA-30.3
Profit Mgn-144.4%
ROE—
Rev Growth2521.2%
Beta1.09
DividendNone
Rating analysts29

Quality Signals

Piotroski F6/9

Options Flow

P/C0.15bullish
IV66%elevated
Max Pain$40-43.8% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductAttruby and Beyonttra
    10-K Item 1A: 'Our business is substantially dependent on the commercial success of Attruby and Beyonttra.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·2 ceiling hits

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Forward Pe
1.0
Peg Ratio
6.3
Analyst Target
9.0
Forward P/E: 134.5xPEG: 1.18
GatesMomentum 2.1<4.5EARNINGS PROXIMITY 5d<=7dA.R:R 2.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60NEWS BOOST ANALYST CLUSTER(3)SEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
41 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $68.35Resistance $84.75

Price Targets

$66
$91
A.Upside+27.6%
A.R:R2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 2.1/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:5d<=7d

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BBIO stock a buy right now?

Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $71.17 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $66.30. Score 5.3/10, moderate confidence.

What is the BBIO stock price target?

Take-profit target: $90.80 (+27.6% upside). Prior stop was $66.30. Stop-loss: $66.30.

What are the risks of investing in BBIO?

Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk); Consecutive earnings misses (2).

Is BBIO overvalued or undervalued?

BridgeBio Pharma, Inc. trades at a P/E of N/A (forward 134.5). TrendMatrix value score: 3.3/10. Verdict: Sell.

What do analysts say about BBIO?

29 analysts cover BBIO with a consensus score of 4.3/5. Average price target: $101.

What does BridgeBio Pharma, Inc. do?BridgeBio Pharma is a commercial-stage biopharmaceutical company whose primary product Attruby (acoramidis) was...

BridgeBio Pharma is a commercial-stage biopharmaceutical company whose primary product Attruby (acoramidis) was FDA-approved in November 2024 for transthyretin amyloid cardiomyopathy, priced at $19,790 per 28-day supply in 2026. The company has treated 8,500+ patients with approved medicines and is advancing multiple Phase 3 rare disease programs. Beyonttra is commercialized in Europe via Bayer and in Japan via Alexion.

Related stocks: HRMY (Harmony Biosciences Holdings, I) · INCY (Incyte Corporation) · CPRX (Catalyst Pharmaceuticals, Inc.) · INVA (Innoviva, Inc.) · AUPH (Aurinia Pharmaceuticals Inc)